Phase II study of topotecan in patients with recurrent malignant glioma

Annals of Oncology

Volumn 7, Issue 2, 1996, Pages 205-207

  Macdonald, D ^a,b   Cairncross, G ^a,b   Stewart, D ^c,d   Forsyth, P ^e,f   Sawka, C ^g,h   Wainman, N ⁱ   Eisenhauer, E ^i,j  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f TOM BAKER CANCER CENTRE   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

ⁱ QUEEN S UNIVERSITY   (Canada)

^j Clinical Trials Group   (Canada)

more..

Author keywords

Malignant glioma; Phase II; Topotecan

Indexed keywords

TOPOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0029915134     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010550     Document Type: Article

References (10)

1. Lock RB, Ross WE. DNA topoisomerases in cancer therapy. Anticancer Drug Design 1987; 2: 151-64.
2. Bums HA, Fields SM. Topoisomerase I inhibitors. An overview of the Camptothecin analogs. New Drug Ther 1994; 8: 333-55.
3. Cairncross JG, Macdonald DR, Pexman JHW et al. Steroid-induced CT scan changes in patients with recurrent malignant glioma. Neurology 1988; 38: 724-6.
4. Watling CJ, Lee DH, Macdonald DR et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol 1994; 12: 1886-9.
5. Macdonald DR, Cascino TL, Schold SC et al. Response criteria for phase II studies of malignant glioma. J Clin Oncol 1990; 8: 1277-80.
6. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up of a new chemotherapeutic agent. J Chron Dis 1961; 13: 346-53.
7. Cascino TL, Kimmel DW, Dmapoli RP et al. Report of four cases with a resolving syndrome which otherwise simulates recurrent brain tumor. Neurology 1988; 38(1): 306.
8. Forsyth P, Kelly PJ, Cascino TL et al. Radiation necrosis or glioma recurrence: Is a computer-assisted sterotactic biopsy useful? J Neurosurg 1995; 82: 436-44.
9. Hochster H, Liebes L, Speyer J et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer. An active and well-tolerated regimen. J Clin Oncol 1994; 12: 553-9.
10. Kim JH, Kim SH, Kolozsvary A et al. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radial Oncol Biol Phys 1992; 22: 515-8.